StockNews.AI
SHPH
StockNews.AI
120 days

Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

1. SHPH will present at Planet MicroCap Showcase on April 23, 2025. 2. Dr. Dritschilo will discuss the Phase 2 trial of Ropidoxuridine. 3. Company aims to improve cancer treatment outcomes with diagnostic innovations. 4. Focus on glioblastoma and prostate cancer diagnostics in upcoming presentation.

6m saved
Insight
Article

FAQ

Why Bullish?

Participation in industry showcases often enhances visibility and investor interest, similar to past instances seen with biotech firms that presented successful trial updates, leading to stock price increases.

How important is it?

The presentation showcases ongoing trials and developments, crucial aspects that can affect investor perception and stock price in the near term.

Why Short Term?

The upcoming presentation has an imminent date, likely generating buzz and momentum in the days leading up to it, similar to past biotech conference presentations that boosted stock performance shortly before events.

Related Companies

SHPHIMUXCRMD
GAITHERSBURG, Md., April 21, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025, at 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time). Anatoly Dritschilo, M.D., Chairman of the Board of Directors and Chief Scientific Officer of Shuttle Pharma, will be hosting the presentation and answering questions at the conclusion. Dr. Dritschilo’s presentation will focus on providing an overview and update on the Company’s ongoing Phase 2 trial of Ropidoxuridine and RT for treatment of patients with glioblastoma as well as advancements being made in the Company’s Shuttle Diagnostics subsidiary which aims to develop pretreatment diagnostic blood tests and imaging agents for prostate cancer patients. To access the live presentation, please use the following information: Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub Date: Wednesday, April 23, 2025 Time: 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time) Location: Track 3 – Chablis at the Paris Hotel & Casino in Las Vegas, NV Webcast: https://event.summitcast.com/view/YNz6mnmEsXyrdRxb78w2nX/Js2DcQMoTdPkzijmn5bhuj If you would like to schedule a 1x1 meeting with management, please contact your Planet MicroCap representative or the Company’s investor relations team at 1x1@lythampartners.com. 1x1 meetings will be scheduled and conducted in person at the conference venue: Paris Hotel & Casino in Las Vegas, NV About Shuttle Pharmaceuticals Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at www.shuttlepharma.com. Safe Harbor Statement Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements concerning the development of our company. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the “Risk Factors” section of Shuttle Pharma’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 26, 2025, as well other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharmaceuticals specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Shuttle PharmaceuticalsAnatoly Dritschilo, M.D.Chairman and Chief Scientific Officer240-403-4212info@shuttlepharma.com Investor ContactsLytham Partners, LLCRobert Blum602-889-9700shph@lythampartners.com 

Related News